title: [Role of viral infections in immunosuppressed patients].
abstract: Being a solid organ and hematopoietic stem cell transplant recipient as well as receiving chemotherapy for a malignant hematological disease clearly predispose the subject to a variety of viral infections, both common and opportunistic diseases. The patient may have acquired these infections from the community as well as from the donor organ (donor-derived infections) and/or from reactivation of an endogenous latent virus. Herpes viruses and especially the cytomegalovirus and Epstein-Barr virus are among the most common of the opportunistic viral pathogens affecting these patients, in addition to respiratory viruses. Treatment consists in antiviral drug therapies combined with the reduction in the degree of the induced immunosuppression. A review of the literature has been performed in order to update the epidemiology, pathogenesis, clinical manifestations and therapeutic approach of the viral infections in these immunocompromised patients.
authors.affiliation: Unidad de Enfermedades Infecciosas, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Salavert
authors.forename: R
authors.initials: R
authors.lastname: Granada
authors.forename: A
authors.initials: A
authors.lastname: Díaz
authors.forename: R
authors.initials: R
authors.lastname: Zaragoza
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D015897:Comorbidity; D003422:Critical Care; D016638:Critical Illness; D003428:Cross Infection / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control / Q000821:virology; D004198:Disease Susceptibility; D006566:Herpesviridae Infections / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects; D008232:Lymphoproliferative Disorders / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology / Q000821:virology; D009894:Opportunistic Infections / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology / Q000821:virology; D011183:Postoperative Complications / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology / Q000821:virology; D012307:Risk Factors; D000069283:Rituximab; D014180:Transplantation; D014412:Tumor Virus Infections / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology; D014777:Virus Diseases / Q000188:drug therapy / Q000453:epidemiology* / Q000276:immunology / Q000517:prevention & control; D017735:Virus Latency
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000998:Antiviral Agents; D007166:Immunosuppressive Agents; D000069283:Rituximab